PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 145
- Registration Number
- NCT01029405
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT01028911
- Locations
- 🇺🇸
Pfizer Investigational Site, Wichita, Kansas, United States
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
Phase 3
Completed
- Conditions
- 13-valent Pneumococcal VaccineImmunizationSafetyAntibody Response
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 263
- Registration Number
- NCT01026038
- Locations
- 🇫🇷
Pfizer Investigational Site, Vitry Sur Seine, France
Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT01026545
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Other: Blood draw
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 962
- Registration Number
- NCT01025336
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2010-06-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT01023100
- Locations
- 🇺🇸
Pfizer Investigational Site, Woburn, Massachusetts, United States
A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2010-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT01020136
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
Phase 1
Completed
- Conditions
- Bacterial InfectionsImmunotherapy, ActiveStaphylococcal InfectionsStaphylococcal Skin InfectionsStaphylococcal Vaccines
- Interventions
- Biological: SA3Ag vaccineBiological: SA3Ag followed by PlaceboBiological: PlaceboBiological: SA3Ag with no booster in stage 2Procedure: Placebo with no booster in stage 2Procedure: Blood drawProcedure: Colonization swab samples
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 449
- Registration Number
- NCT01018641
- Locations
- 🇦🇺
Pfizer Investigational Site, Subiaco, Western Australia, Australia
Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01017926
Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT01015014
- Locations
- 🇦🇺
CMAX, Adelaide, Australia